Crystal Structure of the Human Liver X Receptor β Ligand-binding Domain in Complex with a Synthetic Agonist

Journal of Molecular Biology

Volumn 334, Issue 5, 2003, Pages 853-861

  Hoerer, Stefan ^a   Schmid, Angela ^a   Heckel, Armin ^a   Budzinski, Ralph M ^a   Nar, Herbert ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Crystal structure; Ligand binding domain; Liver X receptor; Nuclear hormone receptor; Transcription factor

Indexed keywords

HORMONE RECEPTOR; LIVER X RECEPTOR BETA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

AGONIST; ALPHA HELIX; ARTICLE; CRYSTAL STRUCTURE; HYDROGEN BOND; HYDROPHOBICITY; LIGAND BINDING; LIPID SOLUBILITY; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STABILITY; RECEPTOR BINDING;

EID: 0345304733     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2003.10.033     Document Type: Article

References (39)

1. Alberti S., Steffensen K.R., Gustafsson J.A. Structural characterisation of the mouse nuclear oxysterol receptor genes LXRalpha and LXRbeta. Gene. 243:2000;93-103.
2. Teboul M., Enmark E., Li Q., Wikstrom A.C., Pelto-Huikko M., Gustafsson J.A. OR-1, a member of the nuclear receptor superfamily that interacts with the 9-cis-retinoic acid receptor. Proc. Natl Acad. Sci. USA. 92:1995;2096-2100.
3. Auboeuf D., Rieusset J., Fajas L., Vallier P., Frering V., Riou J.P., et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes. 46:1997;1319-1327.
4. Willy P.J., Umesono K., Ong E.S., Evans R.M., Heyman R.A., Mangelsdorf D.J. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 9:1995;1033-1045.
5. Fu X., Menke J.G., Chen Y., Zhou G., MacNaul K.L., Wright S.D., et al. 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J. Biol. Chem. 276:2001;38378-38387.
6. Lehmann J.M., Kliewer S.A., Moore L.B., Smith-Oliver T.A., Oliver B.B., Su J.L., et al. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 272:1997;3137-3140.
7. Laffitte B.A., Repa J.J., Joseph S.B., Wilpitz D.C., Kast H.R., Mangelsdorf D.J., Tontonoz P. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc. Natl Acad. Sci. USA. 98:2001;507-512.
8. Venkateswaran A., Repa J.J., Lobaccaro J.M., Bronson A., Mangelsdorf D.J., Edwards P.A. Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages. A transcriptional role for specific oxysterols. J. Biol. Chem. 275:2000;14700-14707.
9. Costet P., Luo Y., Wang N., Tall A.R. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J. Biol. Chem. 275:2000;28240-28245.
10. Attie A.D., Kastelein J.P., Hayden M.R. Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. J. Lipid Res. 42:2001;1717-1726.
11. Schultz J.R., Tu H., Luk A., Repa J.J., Medina J.C., Li L., et al. Role of LXRs in control of lipogenesis. Genes Dev. 14:2000;2831-2838.
12. Terasaka N., Hiroshima A., Koieyama T., Ubukata N., Morikawa Y., Nakai D., Inaba T. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Letters. 536:2003;6-11.
13. Joseph S.B., McKilligin E., Pei L., Watson M.A., Collins A.R., Laffitte B.A., et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl Acad. Sci. USA. 99:2002;7604-7609.
14. Collins J.L., Fivush A.M., Watson M.A., Galardi C.M., Lewis M.C., Moore L.B., et al. Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J. Med. Chem. 45:2002;1963-1966.
15. Wurtz J.M., Bourguet W., Renaud J.P., Vivat V., Chambon P., Moras D., Gronemeyer H. A canonical structure for the ligand-binding domain of nuclear receptors. Nature Struct. Biol. 3:1996;87-94.
16. Tocchini-Valentini G., Rochel N., Wurtz J.M., Mitschler A., Moras D. Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands. Proc. Natl Acad. Sci. USA. 98:2001;5491-5496.
17. Klaholz B.P., Mitschler A., Belema M., Zusi C., Moras D. Enantiomer discrimination illustrated by high-resolution crystal structures of the human nuclear receptor hRARgamma. Proc. Natl Acad. Sci. USA. 97:2000;6322-6327.
18. Ribeiro R.C., Apriletti J.W., Wagner R.L., Feng W., Kushner P.J., Nilsson S., et al. X-ray crystallographic and functional studies of thyroid hormone receptor. J. Steroid Biochem. Mol. Biol. 65:1998;133-141.
19. Cronet P., Petersen J.F., Folmer R., Blomberg N., Sjoblom K., Karlsson U., et al. Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure (Camb). 9:2001;699-706.
20. Watkins R.E., Wisely G.B., Moore L.B., Collins J.L., Lambert M.H., Williams S.P., et al. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science. 292:2001;2329-2333.
21. Stehlin C., Wurtz J.M., Steinmetz A., Greiner E., Schule R., Moras D., Renaud J.P. X-ray structure of the orphan nuclear receptor RORbeta ligand-binding domain in the active conformation. EMBO J. 20:2001;5822-5831.
22. Xu H.E., Lambert M.H., Montana V.G., Plunket K.D., Moore L.B., Collins J.L., et al. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc. Natl Acad. Sci. USA. 98:2001;13919-13924.
23. Renaud J.P., Moras D. Structural studies on nuclear receptors. Cell. Mol. Life Sci. 57:2000;1748-1769.
24. Downes M., Verdecia M.A., Roecker A.J., Hughes R., Hogenesch J.B., Kast-Woelbern H.R., et al. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol. Cell. 11:2003;1079-1092.
25. Egea P.F., Mitschler A., Rochel N., Ruff M., Chambon P., Moras D. Crystal structure of the human RXRalpha ligand-binding domain bound to its natural ligand: 9-cis retinoic acid. EMBO J. 19:2000;2592-2601.
26. Bourguet W., Ruff M., Chambon P., Gronemeyer H., Moras D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha. Nature. 375:1995;377-382.
27. Kallen J.A., Schlaeppi J.M., Bitsch F., Geisse S., Geiser M., Delhon I., Fournier B. X-Ray structure of the hRORalpha LBD at 1.63 Å. Structural and functional data that cholesterol or a cholesterol derivative is the natural ligand of RORalpha. Structure (Camb). 10:2002;1697-1707.
28. Gampe R.T. Jr, Montana V.G., Lambert M.H., Miller A.B., Bledsoe R.K., Milburn M.V., et al. Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol. Cell. 5:2000;545-555.
29. Williams S.P., Bledsoe R.K., Collins J.L., Boggs S., Lambert M.H., Miller A.B., et al. X-ray crystal structure of the liver x receptor ligand binding domain: regulation by a histidine-tryptophan switch. J. Biol. Chem. 278:2003;27138-27143.
30. Janowski B.A., Grogan M.J., Jones S.A., Wisely G.B., Kliewer S.A., Corey E.J., Mangelsdorf D.J. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc. Natl Acad. Sci. USA. 96:1999;266-271.
31. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 389:1997;753-758.
32. Spencer T.A., Li D., Russel J.S., Collins J.L., Bledsoe R.K., Consler T.G., et al. Pharmacophore analysis of the nuclear oxysterol receptor LXRalpha. J. Med. Chem. 44:2001;886-897.
33. Brandstetter H., Turk D., Hoeffken H.W., Grosse D., Sturzebecher J., Martin P.D., et al. Refined 2.3 Å X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA. A starting point for improving antithrombotics. J. Mol. Biol. 226:1992;1085-1099.
34. CCP4 suite: programs for protein crystallography. Acta Crystallog. sect. D. 50:1994;760-763.
35. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallog. sect. D. 53:1997;240-255.
36. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallog. 26:1993;281-291.
37. Kraulis P.J. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallog. 24:1991;946-950.
38. Merritt E.A., Bacon D.J. Raster3D: photorealistic molecular graphics. Methods Enzymol. 1997;505-524.
39. Gouet P., Courcelle E., Stuart D.I., Metoz F. ESPript: analysis of multiple sequence alignments in PostScript. Bioinformatics. 15:1999;305-308.